Record overview
Status and phase
Status: NOT_YET_RECRUITING
Phase: PHASE2
Sponsor: Qilu Hospital of Shandong University
Condition: Muscle Invasive Bladder Cancer (MIBC)
NCT07201675
Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal
Stopped reason
Context when available
No stop reason available in the current public record.